Dalen Meeter - Singular Genomics Chief Officer
| OMICDelisted Stock | USD 20.01 0.00 0.00% |
Executive
Dalen Meeter is Chief Officer of Singular Genomics Systems
| Age | 46 |
| Phone | 858 333 7830 |
| Web | https://www.singulargenomics.com |
Dalen Meeter Latest Insider Activity
Tracking and analyzing the buying and selling activities of Dalen Meeter against Singular Genomics stock is an integral part of due diligence when investing in Singular Genomics. Dalen Meeter insider activity provides valuable insight into whether Singular Genomics is net buyers or sellers over its current business cycle. Note, Singular Genomics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Singular Genomics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Dalen Meeter over three months ago Acquisition by Dalen Meeter of 15000 shares of Singular Genomics subject to Rule 16b-3 | ||
Dalen Meeter over a year ago Acquisition by Dalen Meeter of 240000 shares of Singular Genomics subject to Rule 16b-3 | ||
Dalen Meeter over a year ago Exercise or conversion by Dalen Meeter of 6250 shares of Singular Genomics subject to Rule 16b-3 | ||
Dalen Meeter over a year ago Exercise or conversion by Dalen Meeter of 6250 shares of Singular Genomics subject to Rule 16b-3 |
Singular Genomics Management Efficiency
The company has return on total asset (ROA) of (0.2421) % which means that it has lost $0.2421 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5357) %, meaning that it created substantial loss on money invested by shareholders. Singular Genomics' management efficiency ratios could be used to measure how well Singular Genomics manages its routine affairs as well as how well it operates its assets and liabilities.Singular Genomics Systems currently holds 75.29 M in liabilities with Debt to Equity (D/E) ratio of 0.2, which may suggest the company is not taking enough advantage from borrowing. Singular Genomics Systems has a current ratio of 22.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Singular Genomics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Clay Schwabe | Precision Optics, | N/A | |
| Maik Helmers | LeMaitre Vascular | 51 | |
| Jeyakumar Subbaroyan | Nyxoah | N/A | |
| David Hissong | LeMaitre Vascular | N/A | |
| An Moonen | Nyxoah | N/A | |
| Thomas Adams | Repro Med Systems | 52 | |
| Jeffrey DiRubio | Precision Optics, | N/A | |
| Jacob Petersen | LeMaitre Vascular | 48 | |
| Shiela Vinczeller | AptarGroup | 60 | |
| Christopher Pazdan | Repro Med Systems | 42 | |
| Juan Serna | AngioDynamics | N/A | |
| Mark Fox | Utah Medical Products | N/A | |
| Marna BronfenMoore | AngioDynamics | 58 | |
| Scott Centea | AngioDynamics | 45 | |
| Jerod Funke | InfuSystems Holdings | 50 | |
| Brian Koopman | Utah Medical Products | 55 | |
| Mary Skafidas | AptarGroup | N/A | |
| Jeanie Latz | InfuSystems Holdings | N/A | |
| Marcena Clawson | Utah Medical Products | N/A | |
| Andy Molnar | Milestone Scientific | 62 | |
| Daniel Ackerman | AptarGroup | 52 | |
Management Performance
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.24 |
Singular Genomics Systems Leadership Team
Elected by the shareholders, the Singular Genomics' board of directors comprises two types of representatives: Singular Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Singular. The board's role is to monitor Singular Genomics' management team and ensure that shareholders' interests are well served. Singular Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Singular Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eric Stier, General VP | ||
| Daralyn Durie, G Counsel | ||
| Samuel Ropp, Chief Officer | ||
| Andrew Spaventa, CEO, Founder | ||
| Eli Glezer, Chief Founder | ||
| Dalen Meeter, Chief Officer | ||
| Jeff Bullard, Head Sales | ||
| MBA Velarde, Senior Strategy | ||
| Vincent Brancaccio, Head Resources | ||
| Jyotsna Ghai, Chief Officer | ||
| David Barker, Member Founder |
Singular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Singular Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (44.51) % | ||||
| Current Valuation | (12.58 M) | ||||
| Shares Outstanding | 2.54 M | ||||
| Shares Owned By Insiders | 14.10 % | ||||
| Shares Owned By Institutions | 54.80 % | ||||
| Number Of Shares Shorted | 44.74 K | ||||
| Price To Earning | 35.71 X | ||||
| Price To Book | 0.41 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Singular Stock
If you are still planning to invest in Singular Genomics Systems check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Singular Genomics' history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |